18th Jun 2018 11:21
LONDON (Alliance News) - Shares in hVIVO PLC rose on Monday after the scientific research company announced positive results from the study of its flu vaccine.
Shares were trading up 25% at 24.59 pence following the announcement.
The company said it achieved primary and secondary endpoints of the Phase IIb field study of FLU-v, its broad spectrum universal influenza vaccine.
The study of the vaccine showed induction of long-lasting T & B cell immunological responses, reduction in influenza infection rates and severity and duration of symptoms.
FLU-v, developed by Imutex Ltd, hVIVO's 49% joint venture with the SEEK Group, is now ready for Phase III development, the company said.
SEEK Chief Executive Officer Gregory Stoloff said: "FLU-v is a synthetic polypeptide vaccine which means that it is not reliant on traditional manufacturing techniques with inherent risks, in particular the potential of a miss-match of virus particularly relevant for a pandemic strain.
"FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain."
Related Shares:
hVIVO